NCT03416296

Brief Summary

Placenta accreta occurs when the placental implantation is abnormal. The marked rise in incidence has been assumed the increasing prevalence of cesarean delivery in recent years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 31, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

March 15, 2018

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2019

Completed
Last Updated

September 16, 2021

Status Verified

September 1, 2021

Enrollment Period

1.2 years

First QC Date

January 24, 2018

Last Update Submit

September 15, 2021

Conditions

Morbidly Adherent Placenta

Outcome Measures

Primary Outcomes (1)

  • number of participants who will be diagnosed to have normal placenta or placenta previa or morbidly adherent placenta by US

    within 6 weeks

Study Arms (2)

normal placenta

TA , TV ,TP us

placenta previa and MAP

TA,TV.TP us

Eligibility Criteria

Age20 Years - 43 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailspregnant females with GA above 30 weeks
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

pregnant females with previous cs will be subjected to US to assess placental location and MAP

You may qualify if:

  • pregnant ladies with previous cesarean sections
  • GA above 30 weeks

You may not qualify if:

  • Primigravida patients
  • GA below 30 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Algazeerah

Giza, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

uterus in case of hysterectomy after cesarean hysterectomy

MeSH Terms

Conditions

Placenta Accreta

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPlacenta Diseases

Study Officials

  • Mahmoud Alalfy

    Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital

Study Record Dates

First Submitted

January 24, 2018

First Posted

January 31, 2018

Study Start

March 15, 2018

Primary Completion

June 10, 2019

Study Completion

December 20, 2019

Last Updated

September 16, 2021

Record last verified: 2021-09

Locations

EG(1)